Established patient returns to the eye clinic for complete exam/OCT/photos to 
monitor macular degeneration.

CC: Patient states that vision is stable OU since his last eye exam. Patient has 
intermittent double vision that has been going on for years when not wearing 
glasses and has improved since cataract surgery. Now the double vision is hardly 
ever noticeable. Patient denies any eye pain or irritation, and is not using any 
drops on a regular basis. 

Diabetic Review
- Year diagnosed: N/A; pre-diabetic
- Management: diet controlled
- Most recent blood sugar per patient: unknown
- Most recent HA1c: 6.0% (06/2019) 
 
The patient was last seen on 04/15/19 with Dr. Veres for a VF/DFE.
The patient's last complete exam was on 10/15/18 with Dr. Windham.

OCULAR MEDS:
1. AREDS2 BID PO
        -no refill/renewal needed today
 
The patient is being followed for:
1. NIDDM without retinopathy OU; (-)Clinically significant macular edema OU
2. Hypertension without ocular complications OU
3. Pseudophakia OU
4. Refractive error OU; presbyopia OU
5. Intermediate non-exudative age-related macular degeneration OU; worsening OU
6. Low risk glaucoma suspect secondary to asymmetric cupping OU; stable OU
7. Intermittent alternating exotropia OU; improved symptoms since cataract 
   surgery

REVIEW OF SYSTEMS
 [-]Constitutional 
 [-]ENT
 [+]Cardiovascular:     HTN, hyperlipidemia 
 [+]Respiratory:        Chronic obstructive lung disease
 [-]Gastrointestinal
 [+]Genitourinary:      History of malignant neoplasm of prostate, ED 
                        Calculus of Kidney, prostate cancer
 [+]Musculoskeletal     degenerative joint disease
 [-]Integumentary 
 [-]Neurologic
 [-]Psychiatric
 [+]Endocrine          prediabetes
 [-]Hematologic/Lymph: 
 [-]Autoimmune/Allergic

PAST OCULAR HX: 
 [-]Trauma: 
 [+]Surgery: CE OU 07/2019 at Columbus VA
 [+]Strabismus: lazy eye OS since childhood
 [-]Glaucoma: 
 
FAM. OC HX: 
 [-]Glaucoma 
 [-]Macular Degeneration 
 [-]Blindness 
 [-]Retinal Detachment 
 
PSHX:
 [-]Tobacco 
 [-]ETOH 

Current Medications Reviewed
Allergies - Patient has answered NKA

ORIENTATION: Time/Person/Place
MOOD AND AFFECT: Appropriate 

CURRENT SPECTACLE RX: 10/2018 (pre-cataract surgery OU)
  OD: +4.00 -2.00 X 103  2.5 BI  0.75 BU 
  OS: +3.75 -1.00 X 105  3.5 BI  0.50 BD
  ADD: +2.50

VISUAL ACUITY: without correction in phoropter
         DIST 
  OD    20/30-2
  OS    20/20-2

COVER TEST (without correction):D: 15 IAXT
COVER TEST (with correction):   N: 25 IAXT
EOM AND HIRSCHBERG ALIGNMENT:   Smooth and full w/o Diplopia/Pain; 
                                No apparent tropia OD/OS
CONFRONTATION VISUAL FIELDS:    Full to finger counting OU 
AMSLER GRID:                    Normal OU 
PUPILS:                         Equal round and reactive to light; (-)RAPD
 
REFRACTION AND BEST VISUAL ACUITY: 
  OD: -0.25 -0.50 x 090          20/20-2
  OS: plano -0.25 x 093          20/20-2
  ADD: +2.50

SLIT LAMP EXAM: 
  Lids/Lashes/Ocular Adnexa:    lash debris OU
  Sclera/Conjunctiva:           Clear and quiet OU
  Cornea (epithelium, stroma, endothelium, tear film): arcus OU, EBMD OU
  Anterior Chamber:             Deep/no cells or flare OU
  Iris:                         Flat and intact, no rubeosis OU

TONOMETRY: 
  OD: 14
  OS: 14
   TIME: 9:32

DILATION: 
  1 GTT Tropicamide (1.0%) OU 
  1 GTT Phenylephrine (2.5%) OU 
 
INTERNAL (90D, 20D BIO): 

LENS (anterior/posterior capsule, cortex, nucleus)
 OD: PCIOL; centered; small vertical crack just temp to fixation
 OS: PCIOL; centered

VITREOUS: 
  OD: Syneresis
  OS: Syneresis
 
NERVE: 
  OD: 0.35/0.35 cup/disc ratio (horiz/vert) 
      Normal Color/Margins 
  OS: 0.40/0.40 cup/disc ratio (horiz/vert) 
      Normal Color/Margins 
 
MACULA: 
  OD: No blood, fluid or exudates, scattered intermediate and small hard drusen 
      with pigment clumping/mottling, scattered soft drusen
  OS: No blood, fluid or exudates, scattered intermediate and small hard drusen 
      with pigment clumping/mottling, scattered soft drusen

BLOOD VESSELS: 
  OD: Normal course and caliber
  OS: Normal course and caliber

PERIPHERY: 
  OD: No holes, tears or detachments 
  OS: No holes, tears or detachments

ADDITIONAL TESTS:

 OCT RNFL
   OD: SS: 8/10; 75um avg thickness, borderline thinning superiorly
   OS: SS: 9/10; 74um avg thickness, borderline thinning superior temporal 
       quadrant
        - stable OD/OS to baseline in 2013 per GPA

 OCT MAC
   OD: SS: 10/10; 232um CT; normal foveal contour, intact RPE (-)IRF/SRF/VMT
   OS: SS: 10/10; 230um CT; normal foveal contour, intact RPE (-)IRF/SRF/VMT, 
       irregluar RPE
        - stable OD/OS to scan 10/2018

 FUNDUS PHOTOGRAPHY
   OD: few small hard drusen and intermediate drusen, few soft drusen; 
       stable cupping, pigment mottling
   OS: few small hard drusen and intermediate drusen, few soft drusen; 
        stable cupping, pigment mottling
        - worsening OD/OS to 10/2018

ASSESSMENT: 
1. NIDDM without retinopathy OU; (-)Clinically significant macular edema OU
2. Hypertension without ocular complications OU
3. Pseudophakia OU
4. Refractive error OU; presbyopia OU
5. Intermediate non-exudative age-related macular degeneration OU; worsening OU
6. Low risk glaucoma suspect secondary to asymmetric cupping OU; stable OU
        a. IOP today: 14/14 OD/OS normal, untreated OU
        b. OCT RNFL 9/2019: stable without progression per GPA OU. 
        c. Photos 9/2019: Stable cupping OU
        d. Visual Field 01/2017: normal OU
        e. Gonioscopy 01/2017: open to CB 360 OU
        f. Pachymetry 01/2017: 508/520 OS/OS
7. Intermittent alternating exotropia OU; improved symptoms since cataract 
   surgery

PLAN:
1. Patient educated on findings, benefits of tight glucose control, modifiable 
   risk factors, and the importance of continued follow with primary care 
   physician; monitor at complete.
2. Encouraged good blood pressure control; monitor at complete.
3. Educated patient on good status; monitor at complete.
4. Continue with OTC readers if needed; monitor at complete.
5. Patient education on findings, the benefits/risks of lifestyle modifications 
   and appropriate antioxidant therapy for risk reduction; Rx'ed AREDS2 BID PO 
   every day; continue amsler grid: RTC STAT with changes; otherwise, monitor 
   with DFE in 6 months.
6. Discussed stability; no treatement indicated; monitor with VF in 6 months.
7. Continue without prism at this time; advised to RTC should diplopia re-occur; 
   otherwise monitor at complete.

RTC 04/2020 DFE/24-2 HVF
RTC 09/2020 Complete/OCT/photos